Teva Pharmaceutical Industries Limited (NYSE:TEVA) was downgraded by stock analysts at Credit Suisse Group from an “outperform” rating to a “neutral” rating in a research note issued on Friday, MarketBeat Ratings reports.

Several other research firms have also recently issued reports on TEVA. Vetr cut Teva Pharmaceutical Industries Limited from a “hold” rating to a “sell” rating and set a $32.27 price target for the company. in a research note on Tuesday, July 4th. BidaskClub raised Teva Pharmaceutical Industries Limited from a “hold” rating to a “buy” rating in a research note on Wednesday, July 5th. Wells Fargo & Company reissued a “hold” rating on shares of Teva Pharmaceutical Industries Limited in a research note on Tuesday, June 27th. Cantor Fitzgerald set a $31.00 price target on Teva Pharmaceutical Industries Limited and gave the stock a “hold” rating in a research note on Thursday, June 22nd. Finally, Jefferies Group LLC reissued a “hold” rating and issued a $33.00 price target on shares of Teva Pharmaceutical Industries Limited in a research note on Friday, June 23rd. One investment analyst has rated the stock with a sell rating, twenty-two have assigned a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus target price of $39.81.

Teva Pharmaceutical Industries Limited (TEVA) traded down 13.26% during midday trading on Friday, reaching $20.60. The company’s stock had a trading volume of 93,317,085 shares. The company has a market capitalization of $20.93 billion, a price-to-earnings ratio of 264.10 and a beta of 0.46. The company’s 50-day moving average price is $32.05 and its 200-day moving average price is $32.28. Teva Pharmaceutical Industries Limited has a 1-year low of $20.41 and a 1-year high of $55.45. Teva Pharmaceutical Industries Limited also saw unusually large options trading on Thursday. Stock traders purchased 66,716 put options on the stock. This is an increase of approximately 864% compared to the average daily volume of 6,922 put options.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) last released its quarterly earnings results on Thursday, August 3rd. The company reported $0.99 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $1.06 by $0.07. Teva Pharmaceutical Industries Limited had a positive return on equity of 15.18% and a negative net margin of 25.18%. The business had revenue of $5.69 billion during the quarter, compared to the consensus estimate of $5.72 billion. During the same period in the previous year, the company posted $1.25 EPS. The company’s revenue for the quarter was up 12.9% compared to the same quarter last year. On average, analysts predict that Teva Pharmaceutical Industries Limited will post $4.65 earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: “Teva Pharmaceutical Industries Limited (TEVA) Rating Lowered to Neutral at Credit Suisse Group” was first reported by American Banking News and is the property of of American Banking News. If you are viewing this report on another publication, it was illegally copied and republished in violation of US and international copyright & trademark law. The correct version of this report can be accessed at https://www.americanbankingnews.com/2017/08/06/teva-pharmaceutical-industries-limited-teva-rating-lowered-to-neutral-at-credit-suisse-group.html.

A number of large investors have recently made changes to their positions in the company. Gradient Investments LLC increased its stake in shares of Teva Pharmaceutical Industries Limited by 3,676.5% in the first quarter. Gradient Investments LLC now owns 7,704 shares of the company’s stock valued at $247,000 after buying an additional 7,500 shares in the last quarter. Bank of Montreal Can increased its stake in shares of Teva Pharmaceutical Industries Limited by 5.4% in the first quarter. Bank of Montreal Can now owns 638,426 shares of the company’s stock valued at $20,486,000 after buying an additional 32,960 shares in the last quarter. SOL Capital Management CO increased its stake in shares of Teva Pharmaceutical Industries Limited by 10.1% in the first quarter. SOL Capital Management CO now owns 61,693 shares of the company’s stock valued at $1,980,000 after buying an additional 5,670 shares in the last quarter. Kempner Capital Management Inc. increased its stake in shares of Teva Pharmaceutical Industries Limited by 18.9% in the first quarter. Kempner Capital Management Inc. now owns 200,050 shares of the company’s stock valued at $6,420,000 after buying an additional 31,860 shares in the last quarter. Finally, National Pension Service increased its stake in shares of Teva Pharmaceutical Industries Limited by 8.6% in the first quarter. National Pension Service now owns 732,038 shares of the company’s stock valued at $23,945,000 after buying an additional 57,726 shares in the last quarter. 56.20% of the stock is owned by hedge funds and other institutional investors.

Teva Pharmaceutical Industries Limited Company Profile

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Analyst Recommendations for Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Limited and related companies with MarketBeat.com's FREE daily email newsletter.